AbbVie Phase 1 data shows weight loss with monthly obesity drug

September 30, 2026 5:45 AM

AbbVie (NYSE: ABBV) presented detailed Phase 1 results for its investigational obesity drug ABBV-295 at the European Association for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found